Phase 2 Study of Fingolimod in Lung Cancers

This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.

Trial Details

NCT ID

NCT06424067

Phase

PHASE2

Sponsor

Medical University of South Carolina

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Fingolimod 0.5 milligram (mg) [Gilenya]

Locations (sample)

Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

Voluntary, signed, and dated, Institutional Review Board (IRB) approved consent form in accordance with regulatory and institutional guidelines.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female
18 years of age or older

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →